Italia Markets closed

Biocartis Group NV (0R72.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,7340+0,0143 (+0,83%)
Alla chiusura: 04:40PM GMT
Schermo intero
Chiusura precedente1,7197
Aperto1,7197
DenaroN/D x N/D
LetteraN/D x N/D
Min-Max giorno1,7200 - 1,7200
Intervallo di 52 settimane0,2865 - 1,7200
VolumeN/D
Media Volume74.375
CapitalizzazioneN/D
Beta (5 anni mensile)1,29
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio

    PRESS RELEASE 16 October 2023, 7:00 CEST Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio Mechelen, Belgium, 16 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company, announces the launch of the new Breast Cancer Portfolio during the Breast Cancer Awareness month: the Idylla™ PIK3CA-AKT1 Mutation Assay and, in collaboration with APIS Assay Technologies (‘APIS’), the APIS Breast Cancer Subtyping Kit and t

  • GlobeNewswire

    Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit

    PRESS RELEASE 12 October 2023, 7:00 CEST Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit Mechelen, Belgium, 12 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. (‘APIS’), a private UK based company specializing in molecular diagnostics, today announced the expansion of their partnership1 to include the commercialization of the A

  • GlobeNewswire

    Press Release Biocartis Group NV: Disclosure of transparency notification

    PRESS RELEASE: REGULATED INFORMATION 3 October 2023, 7:00 CEST Disclosure of transparency notification Mechelen, Belgium, 3 October 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous p